한빛사
>
한빛사논문
한빛사논문
- 조회173
강성훈Sung Hoon Kang
성균관대학교 의과대학 삼성서울병원, 고려대학교 의과대학 고대구로병원
Alzheimers. Dement., Nov 13 2024, | https://doi.org/10.1002/alz.14368
Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors
Eun Hye Lee1, Sung Hoon Kang1,2, Daeun Shin1, Young Ju Kim1,3, Henrik Zetterberg4,5,6,7,8,9, Kaj Blennow4,5,10,11, Fernando Gonzalez-Ortiz4,5, Nicholas J. Ashton4,12,13,14, Bo Kyoung Cheon1,3, Heejin Yoo1,3, Hongki Ham3,15, Jihwan Yun16, Jun Pyo Kim1, Hee Jin Kim1,3,15,17, Duk L. Na1,3, Hyemin Jang18, Sang Won Seo1,3,15,19,20 the K-ROAD study group
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
2Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea
3Alzheimer’s Disease Convergence Research Center, Samsung Medical Center, Seoul, South Korea
4Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Göteborg,Sweden
5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Göteborg, Sweden
6Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
7UK Dementia Research Institute at UCL, London, UK
8Hong Kong Center for Neurodegenerative Diseases, Hong Kong, P.R. China
9Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison,Wisconsin, USA
10Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
11Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders,University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China
12King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK
13NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK
14Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
15Neuroscience Center, Samsung Medical Center, Seoul, South Korea
16Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon-si, South Korea
17Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, South Korea
18Department of Neurology, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, South Korea
19Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea
20Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, South Korea
Eun Hye Lee and Sung Hoon Kang contributed equally to this study.
Correspondence : Hyemin Jang, Sang Won Seo
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
2Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea
3Alzheimer’s Disease Convergence Research Center, Samsung Medical Center, Seoul, South Korea
4Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Göteborg,Sweden
5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Göteborg, Sweden
6Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
7UK Dementia Research Institute at UCL, London, UK
8Hong Kong Center for Neurodegenerative Diseases, Hong Kong, P.R. China
9Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison,Wisconsin, USA
10Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
11Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders,University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China
12King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK
13NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK
14Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
15Neuroscience Center, Samsung Medical Center, Seoul, South Korea
16Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon-si, South Korea
17Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, South Korea
18Department of Neurology, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, South Korea
19Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea
20Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, South Korea
Eun Hye Lee and Sung Hoon Kang contributed equally to this study.
Correspondence : Hyemin Jang, Sang Won Seo
Abstract
INTRODUCTION
We aimed to investigate which factors affect plasma biomarker levels via amyloid beta (Aβ)-independent or Aβ-dependent effects and improve the predictive performance of these biomarkers for Aβ positivity on positron emission tomography (PET).
METHODS
A total of 2935 participants underwent blood sampling for measurements of plasma Aβ42/40 ratio, phosphorylated tau 217 (p-tau217; ALZpath), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) levels using single-molecule array and Aβ PET. Laboratory findings were collected using a routine blood test battery.
RESULTS
Aβ-independent factors included hemoglobin and estimated glomerular filtration rate (eGFR) for p-tau217 and hemoglobin, eGFR, and triiodothyronine (T3) for GFAP and NfL. Aβ-dependent factors included apolipoprotein E genotypes, body mass index status for Aβ42/40, p-tau217, GFAP, and NfL. However, these factors exhibited negligible or modest effects on Aβ positivity on PET.
DISCUSSION
Our findings highlight the importance of accurately interpreting plasma biomarkers for predicting Aβ uptake in real-world settings.
We aimed to investigate which factors affect plasma biomarker levels via amyloid beta (Aβ)-independent or Aβ-dependent effects and improve the predictive performance of these biomarkers for Aβ positivity on positron emission tomography (PET).
METHODS
A total of 2935 participants underwent blood sampling for measurements of plasma Aβ42/40 ratio, phosphorylated tau 217 (p-tau217; ALZpath), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) levels using single-molecule array and Aβ PET. Laboratory findings were collected using a routine blood test battery.
RESULTS
Aβ-independent factors included hemoglobin and estimated glomerular filtration rate (eGFR) for p-tau217 and hemoglobin, eGFR, and triiodothyronine (T3) for GFAP and NfL. Aβ-dependent factors included apolipoprotein E genotypes, body mass index status for Aβ42/40, p-tau217, GFAP, and NfL. However, these factors exhibited negligible or modest effects on Aβ positivity on PET.
DISCUSSION
Our findings highlight the importance of accurately interpreting plasma biomarkers for predicting Aβ uptake in real-world settings.
논문정보
- Research article
- 2024년 11월 (BRIC 등록일 2024-11-22)
- 국내 연구진
- 의약학 > 신경의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기
